# An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

> **NCT05663853** · — · COMPLETED · sponsor: **LAPIX Therapeutics Inc.** · enrollment: 137 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05663853
- **Lead sponsor:** LAPIX Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05663853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05663853, "An Observational Biomarker Study in Multiple Sclerosis (MS) Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05663853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*